Somnics Health, a pioneer in next-generation sleep apnea solutions, announces the launch of iNAP Essentials, a breakthrough ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Samsung expands its FDA-authorized Sleep Apnea detection feature to 70 global markets, revolutionizing consumer sleep health ...

Medically reviewed by Sukaina Hasnie, MD Various surgical procedures aim to treat snoring. Depending on the cause and ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

ResMed Inc. ( ASX: RMD) shares are back in form — up more than 75% since bottoming out in October 2023.

A recent post-hoc analysis of the SURMOUNT-OSA trials revealed that tirzepatide significantly improves obstructive sleep ...

CI Insights From Zepbound to AD109, pharma innovation is reshaping Obstructive Sleep Apnea. Discover key players, C ...

Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

With the FDA authorization in place, Incannex will initiate Phase 3 immediately following the completion of Phase 2, leveraging a shared protocol and U.S. based infrastructure to maximize efficiency ...

Patients treated with AD109 saw a 55.6% mean reduction in AHI from baseline ... neuromuscular root cause of airway obstruction in sleep apnea and holds promise for transforming care for a broad ...